semaglutide fda approval mash Approves for With Fibrosis FDA grants the first GLP-1

Morning injections allow any side effects to peak during waking hours when they can be managed actively

A 2023 study found that GLP-1 weight-loss therapy was linked to a small but increased risk of serious GI events, including a higher risk of intestinal obstruction compared to other weight-loss drugs

The characteristics of the selected studies are provided in Tables 2 and 3

However, non-pulmonary vein triggers are present in 1033% of patients, particularly in those with persistent AF, in whom AF recurrence rates after pulmonary vein ablation are usually higher than in patients with paroxysmal AF 53

Zepbound reduces appetite, and attempting to eat normal pre-treatment portions can cause significant discomfort, nausea, and vomiting

A Shifting Liability Landscape Product liability risks are entering a new phase of complexity